Hwu, Chii-Min

Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation

Mahajan, A., Spracklen, C. N., Zhang, W., Ng, M. C. Y., Petty, L. E., Kitajima, H., Yu, G. Z., Rüeger, S., Speidel, L., Kim, Y. J., et al. (2022) · Nature Genetics

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 704

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 684

Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

Suzuki, K., Hatzikotoulas, K., Southam, L., Taylor, H. J., Yin, X., Lorenz, K. M., Mandla, R., Huerta-Chagoya, A., Melloni, G. E. M., Kanoni, S., et al. (2024) · Nature

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 606

Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes

Yen, F.-S., Hou, M.-C., Cheng-Chung Wei, J., Shih, Y.-H., Hsu, C. Y., Hsu, C.-C., & Hwu, C.-M. (2024) · Clinical Gastroenterology and Hepatology

Diabetes Treatment and ManagementLiver Disease and Transplantation

Cited by 73

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies

Catapano, A. L., Mikhailova, E., Navar, A. M., Banka, P., Corral, P., Saxena, M., Steg, P. G., Verma, S., Kordahi, A. Y., Mendizabal, G., et al. (2026) · JACC

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 19